Udrea Ana-Maria, Bilea Florin, Avram Speranta, Staicu Angela
National Institute for Lasers, Plasma and Radiation Physics, 409 Atomistilor Str., 077125 Magurele, Romania.
Department of Anatomy, Animal Biology, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, 91-95 Independentei Sp., 050095 Bucharest, Romania.
Int J Mol Sci. 2025 Jul 11;26(14):6668. doi: 10.3390/ijms26146668.
Breast cancer treatments, such as chemotherapy, radiation, and surgery, often face significant limitations, highlighting the need for more effective and targeted therapies. Here, we investigate the potential of 266 nm laser irradiation of chlorpromazine as a novel approach to develop new antitumoral compounds. We identify six chlorpromazine photocompounds with masses in the range of 178-334 u, along with several dimeric compounds with masses between 566 and 600 u, using an HPLC-MS. In silico approaches assess their pharmacokinetic and pharmacodynamic properties while comparing their toxicity with the parent compound. Molecular docking simulations indicate that some photoproducts have a low estimated free energy of binding to cancer-related targets, suggesting enhanced therapeutic potential compared to chlorpromazine. Additionally, ADME-Tox predictions indicate that these photoproducts may have pharmacokinetic and toxicity profiles similar to chlorpromazine. Overall, this study highlights that laser-generated chlorpromazine photoproducts exhibit enhanced biological activity to breast cancer-related targets compared to chlorpromazine while maintaining a similar ADME-Tox profile.
乳腺癌治疗方法，如化疗、放疗和手术，往往面临重大局限性，这凸显了对更有效、更具针对性疗法的需求。在此，我们研究了用266纳米激光照射氯丙嗪作为开发新型抗肿瘤化合物的一种新方法的潜力。我们使用高效液相色谱-质谱法鉴定出六种质量在178 - 334 u范围内的氯丙嗪光化合物，以及几种质量在566至600 u之间的二聚体化合物。计算机模拟方法评估了它们的药代动力学和药效学特性，同时将它们的毒性与母体化合物进行比较。分子对接模拟表明，一些光产物与癌症相关靶点结合的估计自由能较低，这表明与氯丙嗪相比具有更高的治疗潜力。此外，药物代谢动力学-毒理学预测表明，这些光产物可能具有与氯丙嗪相似的药代动力学和毒性特征。总体而言，这项研究强调，与氯丙嗪相比，激光产生的氯丙嗪光产物对乳腺癌相关靶点表现出更强的生物活性，同时保持相似的药物代谢动力学-毒理学特征。
